Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jee-Young | - |
dc.contributor.author | Ma, Hyeo-Il | - |
dc.contributor.author | Ferreira, Joaquim J | - |
dc.contributor.author | Rocha, José-Francisco | - |
dc.contributor.author | Sung, Young Hee | - |
dc.contributor.author | Song, In-Uk | - |
dc.contributor.author | Ahn, Tae-Beom | - |
dc.contributor.author | Kwon, Do Young | - |
dc.contributor.author | Cheon, Sang-Myung | - |
dc.contributor.author | Kim, Jong-Min | - |
dc.contributor.author | Lee, Chong Sik | - |
dc.contributor.author | Lee, Phil Hyu | - |
dc.contributor.author | Park, Jeong-Ho | - |
dc.contributor.author | Lee, Jae-Hyeok | - |
dc.contributor.author | Park, Mee Young | - |
dc.contributor.author | Kim, Sang Jin | - |
dc.contributor.author | Baik, Jong Sam | - |
dc.contributor.author | Choi, Seong-Min | - |
dc.contributor.author | Shin, Hae-Won | - |
dc.contributor.author | Lee, Ho-Won | - |
dc.contributor.author | Kang, Suk Yun | - |
dc.contributor.author | Jeon, Beomseok | - |
dc.date.accessioned | 2024-04-24T08:30:26Z | - |
dc.date.available | 2024-04-24T08:30:26Z | - |
dc.date.issued | 2024-06 | - |
dc.identifier.issn | 2330-1619 | - |
dc.identifier.issn | 2330-1619 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73469 | - |
dc.description.abstract | BACKGROUND: Increasing levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol-O-methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing-off symptoms in Parkinson's disease (PD) patients. OBJECTIVE: To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing-off in PD patients. METHODS: ADOPTION was a randomized, parallel-group, open-label, Phase 4 study conducted in Korea. At baseline, eligible patients were randomized (1:1) to opicapone 50 mg (n = 87) or L-dopa 100 mg (n = 81) (added to current L-dopa/DDCI therapy) for 4 weeks. The main efficacy endpoint was change from baseline to end of study in absolute off time. Other endpoints included changes in on time, in Movement Disorder Society-Unified Parkinson's Disease Rating Scale and 8-item PD Questionnaire scores, and the Clinical and Patient Global Impression of Improvement/Change. RESULTS: The adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L-dopa 100 mg (-62.1 vs. -16.7 minutes; P = 0.0015). Opicapone-treated patients also reported a greater reduction in the percentage of off time (P = 0.0015), a greater increase in absolute on time (P = 0.0338) and a greater increase in the percentage of on time (P = 0.0015). There were no significant differences in other secondary endpoints. The L-dopa equivalent daily dose was significantly higher in the opicapone group (750.9 vs. 690.0 mg; P = 0.0247), when a 0.5 conversion factor is applied. CONCLUSIONS: Opicapone 50 mg was more effective than an additional 100 mg L-dopa dose at decreasing off time in patients with PD and early wearing-off. © 2024 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/mdc3.14030 | - |
dc.identifier.bibliographicCitation | Movement disorders clinical practice, v.11, no.6, pp 655 - 665 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001198893300001 | - |
dc.identifier.scopusid | 2-s2.0-85190436401 | - |
dc.citation.endPage | 665 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 655 | - |
dc.citation.title | Movement disorders clinical practice | - |
dc.citation.volume | 11 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Parkinson's disease | - |
dc.subject.keywordAuthor | levodopa | - |
dc.subject.keywordAuthor | opicapone | - |
dc.subject.keywordAuthor | wearing off | - |
dc.subject.keywordPlus | CATECHOL-O-METHYLTRANSFERASE | - |
dc.subject.keywordPlus | PARKINSONS-DISEASE | - |
dc.subject.keywordPlus | MOTOR FLUCTUATIONS | - |
dc.subject.keywordPlus | LEVODOPA | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | ADJUNCT | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.